All studies
RecruitingPHASE2, PHASE3INTERVENTIONAL

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This research study, called HARBOR, is looking into a new medicine called elenestinib (also known as BLU-263) for people with indolent systemic mastocytosis (ISM) or smoldering systemic mastocytosis (SSM). These are rare conditions where certain immune cells, called mast cells, build up in the body. The study aims to see how well elenestinib works and if it's safe compared to a placebo (a dummy pill) for patients whose symptoms aren't fully managed by their current treatments. Some parts of the study will involve patients with ISM, while another part will look at patients with SSM. All participants will continue their usual symptom-directed therapies while taking part.

At a glance

Status
Recruiting
Phase
PHASE2, PHASE3
Sponsor
Blueprint Medicines Corporation
Enrolment target
534
Start
30 Nov 2021
Estimated completion
30 Sep 2032

What is this study about?

This study is called HARBOR, and it's looking into a new medicine for a rare condition affecting the blood, called systemic mastocytosis. Specifically, it's focused on two types: indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM). These conditions happen when special immune cells, called mast cells, build up too much in different parts of your body. These extra mast cells can cause various symptoms like skin rashes, stomach problems, and bone pain.

The main goal of this study is to test a new medicine called elenestinib (you might also see it referred to by its research name, BLU-263). We want to find out how well it works to control the symptoms of ISM and SSM, and if it's safe, especially for people whose current medicines aren't fully helping. To do this, some people will receive elenestinib, and others will receive a placebo, which looks like the real medicine but doesn't contain any active drug. This helps us fairly compare the new medicine's effects. Everyone in the study will also continue their usual treatments that help manage their symptoms.

This study has a few different stages. In some stages, participants with ISM will be randomly assigned to either receive elenestinib or the placebo. After completing this initial stage, those who were on placebo will then have the chance to receive elenestinib. There's also a specific part of the study for people with ISM who have tried another approved medicine for this condition before. Additionally, some parts of the study will help us understand how the new medicine moves through the body, which is important for understanding how it works.

Key takeaways

  • This study is testing a new medicine called elenestinib for a rare condition called indolent systemic mastocytosis (ISM).
  • It aims to see if elenestinib can better control symptoms not fully managed by current treatments.
  • Some patients will receive the new medicine, and others a placebo (dummy pill), along with their usual care.
  • Participation involves regular clinic visits, blood tests, and health checks.
  • There are specific health requirements to join, and you can leave the study at any time.
  • Your contribution could help advance treatments for systemic mastocytosis.

Who may be eligible?

To be able to join this study, you would generally need to be an adult (18 years or older) and have a confirmed diagnosis of indolent systemic mastocytosis (ISM) or smoldering systemic mastocytosis (SSM) by a specialist. For most parts of the study, you would need to have ISM and your current treatments for symptoms, such as allergy medicines or stomach protectors, shouldn't be fully controlling your symptoms. This means you still experience ongoing problems despite trying at least two different symptom-managing therapies.

Your general health also needs to be good enough to participate, meaning you should be able to carry out most daily activities without too much difficulty. If you are taking steroid medications for your symptoms, the dose needs to be stable and not too high. Your current symptom-managing medication regimen also needs to have been stable for at least two weeks before joining.

There are also reasons why you might not be able to join. For example, if your mastocytosis is a more severe type or if it's linked to other specific blood conditions, you wouldn't be eligible. You also can't have serious heart problems or have had certain types of cancer within the last three years. The study doctors will carefully check your medical history to make sure it's safe for you to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you an adult (18 or older)?
  2. Have you been diagnosed with indolent systemic mastocytosis (ISM) or smoldering systemic mastocytosis (SSM)?
  3. Are your current symptom-managing medications not fully controlling your symptoms?
  4. Is your general health good enough for you to move around and do daily activities (ECOG 0-2)?
  5. Do you have stable doses of any steroid medications you might be taking for your symptoms?
  6. Have you *not* been diagnosed with a more aggressive type of mastocytosis or certain other blood conditions?
Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will likely be involved for several months, possibly over a year, depending on which part of the study you join. Your involvement will typically include:

* **Initial health checks:** Before starting, you'll have various tests like blood tests, heart checks (ECG), and physical exams to ensure the study is safe and right for you. * **Taking the study medicine:** You'll receive either elenestinib or a placebo (a dummy pill) as prescribed, which you'll take at home. You'll continue taking your usual medicines for your symptoms as well. * **Regular clinic visits:** You'll have scheduled appointments at the study clinic throughout your participation. At these visits, doctors and nurses will monitor your health, check for any side effects, ask about your symptoms, and take blood samples. These visits help the study team understand how the medicine is working and ensure your safety. * **Follow-up:** After you stop taking the study medicine, you'll have some follow-up visits or calls to track your health and any lingering effects. * **Total duration:** The exact length of your participation will be explained by the study team, but it can range from several months to over a year, including the initial treatment period and follow-up.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study is that the new medicine, elenestinib, might help to better control your symptoms of indolent systemic mastocytosis if your current treatments aren't fully effective. You would also be contributing to medical research that could help others with your condition in the future. However, there's no guarantee the medicine will work for you, and there's a chance you could receive the placebo. Potential risks include experiencing side effects from the study medicine, which will be carefully monitored by the study team. All participants have the right to withdraw from the study at any time, for any reason, without it affecting their usual medical care.

Locations (68)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • University of Alabama at Birmingham
    Verified postcode
    Birmingham, United States· Recruiting
  • David Geffen School of Medicine at UCLA
    Verified postcode
    Los Angeles, United States· Recruiting
  • Stanford Cancer Institute
    Verified postcode
    Palo Alto, United States· Recruiting
  • UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
    Verified postcode
    Aurora, United States· Recruiting
  • Winship Cancer Institute, Emory University
    Verified postcode
    Atlanta, United States· Recruiting
  • Brigham and Women's Hospital
    Verified postcode
    Boston, United States· Recruiting
  • Michigan Medicine University of Michigan
    Verified postcode
    Ann Arbor, United States· Recruiting
  • Mayo Clinic
    Verified postcode
    Rochester, United States· Recruiting
  • Roswell Park Cancer Institute
    Verified postcode
    Buffalo, United States· Recruiting
  • Columbia University Medical Center
    Verified postcode
    New York, United States· Recruiting
  • Duke Asthma, Allergy and Airway Center
    Verified postcode
    Durham, United States· Recruiting
  • University of Cincinnati Medical Center
    Verified postcode
    Cincinnati, United States· Recruiting

Common questions

What is indolent systemic mastocytosis?

It's a rare condition where too many mast cells (a type of immune cell) build up in different parts of your body, which can cause various symptoms like skin rashes, itching, stomach upset, or bone pain.

What is a placebo?

A placebo is a dummy pill that looks exactly like the real medicine but contains no active drug. It helps researchers fairly compare the new medicine's effects.

Will I still take my regular medication if I join?

Yes, you will continue your usual symptom-directed treatments for mastocytosis while participating in this study alongside the new study medicine or placebo.

What is the new medicine called?

The new medicine being tested is called elenestinib, and its research name is BLU-263.

Can I leave the study at any time?

Yes, you are free to leave the study at any point, for any reason, and it will not affect your regular medical care.

How to find out more

Blueprint Medicines

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Ve…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.